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Coordinating the balance between haematopoietic stem cell (HSC) quiescence and 
self-renewal is crucial for maintaining haematopoiesis lifelong.  Equally important 
for haematopoietic function is modulating their localisation within their bone 
marrow niches, as maintenance of HSC function is tightly controlled by a complex 
network of intrinsic molecular mechanisms and extrinsic signalling interactions 
with their surrounding microenvironment. Recent findings have suggested that a 
common mediator of these functions is the CXCR4-CXCL12 axis. In the first part 
of the dissertation, we demonstrate that nuclear factor erythroid 2-related factor 2 
(Nfe2l2, or Nrf2), well-established as a global regulator of oxidative stress 
response, plays a regulatory role in all these aspects of HSC homeostasis. Nrf2-
deficiency results in an expansion of haematopoietic stem and progenitor cells 
(HSPCs) due to cell-intrinsic hyperproliferation, which was accomplished at the 
expense of HSC quiescence and self-renewal.  We further show that Nrf2 mediates 
both migration and retention of HSCs in their niche.  Moreover, we identify a 
previously unrecognized link between Nrf2 and CXCR4, contributing, at least 
partially, to the maintenance of the main modalities of HSC function.  
 
	  While there is mounting evidence including ours suggesting a critical role of Nrf2 
in HSC homeostasis and lymphohematopoietic malignancies, little is known about 
its role in T-cell biology. In the second part of the dissertation, we evaluate the 
relative contribution of Nrf2 to alloreactive T cells in the context of allogeneic 
bone marrow transplant (allo-BMT). Allogeneic bone marrow transplant (allo-
BMT) is the most potent modality of cellular immune therapy for 
lymphohematologic malignancies.  The therapeutic benefits of allo-BMT are 
derived from the cytoreductive conditioning, as well as the immune-mediated 
graft-versus-tumor (GVT) effect. However, one of the main drawbacks to the 
widespread use of allo-BMT is graft-versus-host disease (GVHD). Allogeneic 
donor T (allo-T) lymphocytes are the primary mediators facilitating both GVT and 
GVHD responses.  We validate the biological significance of Nrf2 in T 
lymphocytes by showing nuclear translocation of Nrf2 upon T cell activation in 
vitro, and an increased cellular Nrf2 level specifically within CD4+ donor T cells 
upon alloactivation in vivo. We demonstrate that Nrf2-deficiency in donor T cells 
leads to attenuated acute GVHD, which is associated with stabilization of Helios+ 
regulatory T cells, present in the graft at the time of transplant, as well as defective 
upregulation of the gut homing receptor LPAM-1 of CD8+ allo-T cells. However, 
Nrf2-/- donor CD8+ T cells possess intact killing ability against alloantigens and 
A20 lymphoma cells.  With their preserved GVT activity and ameliorated GVHD 
severity, Nrf2-/- donor T cells conferred an overall improved survival in the tumor-
bearing allo-BMT recipients. Our findings not only characterize a novel role of 
Nrf2 in T cell function, but also reveal an exciting target for therapeutic 
manipulation as a useful clinical strategy to improve the outcomes of allo-BMT.  
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CHAPTER ONE 
Introduction 
 
Hematopoiesis 
Hematopoiesis is supported by HSCs that are fundamentally characterized by their 
ability to self-renew and potency to differentiate into all blood lineages. 
Postnatally the most quiescent HSCs reside in a relatively hypoxic 
microenvironmental niche in the bone marrow1,2 and are capable of sustaining 
lifelong hematopoiesis. Maintenance of HSC functions, including their 
localization, quiescence, self-renewal, and differentiation, is finely regulated by a 
complex network of intrinsic molecular mechanisms and extrinsic signaling 
interactions with their surrounding microenvironment (Kiel and Morrison, 2008). 
The interaction between the chemokine receptor CXCR4, expressed on the surface 
of HSCs, and its ligand CXCL12, produced by the bone marrow niche, has been 
well described as regulating homing, localization and retention of HSCs in their 
niche. Moreover, recent studies have demonstrated that conditional deletion of 
CXCR4 or CXCL12 in young adult mice leads to hyperproliferation of 
hematopoietic stem and progenitor cells (HSPCs) at the expense of HSC 
quiescence and self-renewal (Nie et al., 2008; Sugiyama et al., 2006; Tzeng et al., 
2011), demonstrating the complex linkages in the main modalities of HSC 
function.  
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In addition to these extrinsic cues that regulate HSC function, mounting evidence 
supports an essential role for intracellular redox balance in maintaining stem cell 
quiescence and stemness. Previous studies indicate that low oxygen concentration 
is critical for maintaining stem cell quiescence in various tissues (Ezashi et al., 
2005; Mazumdar et al., 2010; Yun et al., 2005; Yun et al., 2002), including the 
bone marrow niche (Takubo et al., 2010). Reactive oxygen species (ROS), natural 
metabolites of oxygen under physiological conditions, have recently been shown to 
prime HSPCs for differentiation in Drosophila (Owusu-Ansah and Banerjee, 
2009). In mouse models, disruption of oxidative stress pathways leads to 
premature HSC senescence due to loss of HSC quiescence and decline in the 
capacity for self-renewal (Ito et al., 2004; Ito et al., 2006; Tothova et al., 2007). 
Taken together, these findings indicate that modulation of the redox balance plays 
a pivotal role in maintaining HSC functions. 
 
The Transcription Factor Nrf2 
Nuclear factor erythroid 2-related factor 2 (Nfe2l2, or Nrf2) belongs to the "cap-n-
collar" subfamily of the basic leucine zipper (b-Zip) transcription factors (Moi et 
al., 1994), and is a master regulator in the antioxidant response pathway (Li and 
Kong, 2009; Nguyen et al., 2009). In the basal resting state, Nrf2 is constitutively 
expressed but rendered inactive by sequestration in the cytosol by the 
cytoskeleton-associated protein, Kelch-like ECH-associated protein 1 (Keap1) 
(Itoh et al., 1999). In response to oxidative stress, Nrf2 translocates from the 
cytosol into the nucleus and binds to Antioxidant Response Element (ARE), a cis-
acting DNA regulatory element located in the upstream promoter region of many 
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genes encoding for Phase II detoxifying and antioxidant enzymes, where it drives 
their transcription (Itoh et al., 1997). The resultant induction of Nrf2 target genes 
therefore provides an essential mechanism for cellular defense against oxidative 
stress.  
 
Nrf2 and Hematopoiesis 
Despite its ubiquitous expression in all tissues, Nrf2 was found to be dispensable 
for murine development, growth and erythropoiesis (Chan et al., 1996). Dual roles 
of Nrf2 have been observed in its regulation in differentiation in various tissues. 
While Nrf2 was found to promote differentiation of neuronal cells and adipocytes 
(Pi et al., 2010; Zhao et al., 2009), it was also reported to inhibit differentiation of 
chondrocytes and osteoblasts (Hinoi et al., 2006; Hinoi et al., 2007). Due to the 
continual requirement for HSC protection from oxidative stress, along with recent 
findings that Nrf2 maintains homeostatic quiescence of intestinal stem cells in 
Drosophila (Hochmuth et al., 2011), we sought to assess the role of Nrf2 in 
regulating HSPC functions.  
Allogeneic Bone Marrow Transplant 
Allogeneic bone marrow transplant (allo-BMT) is the most potent modality of 
cellular immune therapy for hematologic malignancies and certain metastatic solid 
tumors.  The therapeutic benefits of allo-BMT are derived from the high dose of 
cytoreductive conditioning, as well as the immune-mediated graft-versus-tumor 
(GVT) effect.  However, the flip side to the beneficial effects of GVT is acute 
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graft-versus-host disease (GVHD), which is a systemic inflammatory disease 
characterized by profound immunosuppression and host tissue damage affecting up 
to 40-60% of allo-BMT patients and accounting for 15% of deaths after allo-
BMT3, limiting the success and wider application of allo-BMT despite its curative 
potential for malignancies refractory to all other treatments.  Allogeneic donor T 
lymphocytes are the primary mediators facilitating both GVT and GVHD 
responses4.  It is therefore not surprising that separation of the undesired GVHD 
and beneficial GVT activities of allo-T cells has attracted intense research pursuits, 
and remains paramount for improving clinical outcomes in patients with 
malignancies treated with allo-BMT.   
Nrf2 and T-cell Alloreactivity 
Nuclear factor erythroid-derived 2-like 2 (NFE2L2, or Nrf2) is a ubiquitously 
expressed basic leucine zipper transcription factor well-established as a master 
regulator of cellular redox, detoxification, and stress pathway.  The dual roles of 
Nrf2 in cancer promotion and cancer prevention in various solid tumors have been 
widely studied for its importance in tumorigenesis5,6.  Moreover, we and others 
have recently shown that Nrf2 positively regulates the self-renewal ability of 
hematopoietic stem cells7.  Consistent with our findings, high levels of Nrf2 
expression have been identified in various hematologic malignancies8-13.  It has 
also been proposed that the increased activity of Nrf2 underlies the 
chemoresistance of leukemia/lymphoma cells to apoptosis.  Although previous 
studies have implicated the involvement of Nrf2 in T cell activation in vitro, 
detailed characterization of its role in T cell function in vivo is still lacking 14-16.      
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While inhibition of Nrf2 pathway represents a rational therapeutic approach 
against hematologic malignancies, we investigated its impact on allo-BMT, the 
definitive curative antitumor therapy for the majority of hematologic cancers. 
Specifically, we hypothesized that Nrf2 may be involved in T-cell alloreactivity 
and cytotoxicity. In this study, we sought to methodically analyze the effects of 
Nrf2 disruption in donor T cells on their abilities to proliferate, to activate, to 
polarize, to kill, and ultimately to cause GVHD and GVT using genetically altered 
Nrf2-/- mice.  
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CHAPTER TWO 
Nrf2 Regulates HSC Function 
 
Nrf2-/- Mice Exhibit an Expanded Haematopoietic Stem and Progenitor Pool 
To determine whether Nrf2 plays a role in haematopoiesis, we first quantified the 
primitive HSPCs in Nrf2-/- mice in steady-state conditions.  In young adult Nrf2-
deficient animals, we observed an increase in both percentage and absolute number 
of LSK (Lineage-Sca-1+c-Kit+) cells compared to age-matched Nrf2+/+ wild-type 
(WT) controls (Figure 1.1 a, b), although overall BM cellularity was unchanged 
(data not shown).  More comprehensive analysis of the LSK fraction revealed 
significant increases at the short-term HSC (ST-HSC, CD34+Flt3-) and continued 
through multipotent progenitor (MPP, CD34+Flt3+) stages, but did not impact on 
long-term HSCs (LT-HSC, CD150+CD48-CD34-Flt3-) (Figure 1.1 c).  We also 
found increases in the number of committed downstream progenitors of both the 
myeloid and lymphoid lineages (Figure 1.1 d, e).  Consistent with these findings, 
we also observed significantly increased colony formation from Nrf2-/- BM in 
cobblestone area-forming cell (CAFC) and colony-forming cell (CFC) assays 
(Figure 1.1 f, g).  Together, these results suggest that loss of functional Nrf2 leads 
to expansion of the haematopoietic progenitor pool but spares the most primitive 
LT-HSCs.  
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Figure 1.1 Nrf2-/- Mice Exhibit an Expanded Haematopoietic Stem and 
Progenitor Pool 
WT and Nrf2-/- bone marrow (BM) under steady-state were examined from 8-10 
week old female mice.  (a) Representative flow cytometric analysis comparing WT 
to Nrf2-/- LSK frequency, gated on lineage- (Lin-) cells.  (b - e) Absolute number of 
LSK cells (b), HSC subsets (c), myeloid progenitors (d) or lymphoid progenitors 
(e), mean + SEM of data from 8 animals per strain over 2 independent 
experiments.  CMP, Common myeloid progenitor (Lin-c-kit+Sca-1-
CD34+CD16/32mid); GMP, Granulocyte-macrophage progenitor (Lin-c-kit+Sca-1-
CD34+CD16/32high); MEP, Megakaryocyte-erythroid progenitor (Lin-c-kit+Sca-1-
CD34-CD16/32low); LMPP, Lymphoid-primed multipotent progenitor (Lin-c-
kit+Sca-1+CD34+Flt3+CD62Lhigh); CLP, Common lymphoid progenitor (CLP-1: 
Lin-IL-7Ra+c-kit+; CLP-2: Lin-IL-7Ra+B220+).  (f) Number of colonies formed 
from WT or Nrf2-/- BM in cobblestone area-forming cells assay (CAFC), mean + 
SEM of data from 11 animals per strain over 3 independent experiments.  MNCs, 
Mononucleated cells.  (g) Number of colonies formed from WT or Nrf2-/- BM in 
myeloid (CFU-GM), erythroid (BFU-E), and mixed (CFU-Mix) lineages in colony-
forming cell assay (CFC), data represent mean + SEM from 13 WT and 12 Nrf2-/- 
mice over 3 independent experiments.  
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Nrf2 Regulates HSPC Proliferation and Differentiation Intrinsically 
To test the impact of Nrf2 on HSPC function, we co-cultured sorted LSK cells 
from Nrf2-/- (CD45.2) and WT (CD45.1) BM in a competitive setting on OP9-DL1 
culture, which allows the in vitro analysis of T cell development from HSPCs.  As 
expected given their increased number in vivo (Figure 1.1), even when seeded in 
equal numbers, Nrf2-/- LSKs dominated the culture as early as day 3 (Figure 1.2, a, 
b), indicating a competitive advantage in proliferation as a result of Nrf2 
deficiency.  T cell development progresses through a series of distinct stages that 
can be identified based on their differential expression of CD4, CD8, CD25 and 
CD44 17.  In addition to their enhanced proliferation, we also observed that Nrf2-/- 
LSKs had enhanced differentiation kinetics compared to WT controls (Figure 1.2, 
c, d), rapidly progressing to the DN2 (CD4-CD8-CD44+CD25+) and DN3 (CD4-
CD8-CD44-CD25+) stages.  Moreover, we found significantly increased expression 
of Ki-67 on LSKs from Nrf2-/- compared with WT BM in vivo (Figure 1.2, e), in 
concordance with the enhanced proliferation observed in vitro. 
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Figure 1.2. Rapid Proliferation and Differentiation of Nrf2-/- HSPCs in vitro 
Sorted BM LSK cells were seeded onto OP9-DL1 stromal cells. (a-b) Relative 
contribution of Nrf2-/- (CD45.2) and WT (CD45.1) cells when co-cultured at a 1:1 
ratio on day 0; (c) Differentiation of WT or Nrf2-LSKs cultured for 5 days, gated 
on double-negative (DN, CD4-CD8-) population, and (d) Percentage	   of	   LSKs	  
differentiating	  into	  DN2	  stage	  on	  day	  5.	   (a-d) Data	  represent	  the	  mean	  +	  SEM,	  n	  
=	  7	  independent	  observations	  over	  4	  experiments.	  (e) Expression of Ki-67 in WT 
and Nrf2-/- BM LSKs, representative plot (left) and bar graph (right) showing mean 
+ SEM of 4 animals per strain over 2 independent experiments. 
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Given the ubiquitous expression of Nrf2, it is essential to clarify whether these 
differences in HSPC proliferation and differentiation kinetics are caused 
extrinsically by the BM niche or intrinsically by the HSPC itself.  To assess the 
role of the BM niche, we generated chimeras using CD45.1+ WT LSKs transferred 
into either CD45.2+ WT or CD45.2+ Nrf2-/- hosts.  After 8 weeks, which allowed 
for effective primary reconstitution, we sorted LSKs from these chimeric mice and 
co-cultured them with OP9-DL1 stromal cells.  Transplanted CD45.1+ WT LSKs 
behaved in a similar manner irrespective of their pre-conditioning 
microenvironment (Figure 1.3, a - d).  In contrast, when we performed the 
reciprocal chimeric experiment where CD45.2+ WT or CD45.2+ Nrf2-/- LSKs, 
previously primed in CD45.1+ WT hosts, were co-cultured on OP9-DL1 stromal 
cells, we discovered once again that transplanted CD45.2+ Nrf2-/- LSKs 
proliferated more and differentiated faster than transplanted Nrf2+/+ WT LSKs 
(Figure 1.3, e - h).  Taken together, these results suggest that Nrf2 regulates 
proliferation and differentiation of HSPCs in a cell-intrinsic manner.   
Figure 1.3. Nrf2 Regulates HSPC Proliferation and Differentiation Intrinsically 
(a - d)  CD45.1+ WT LSKs were preconditioned in CD45.2+ WT or Nrf2-/- animals 
in vivo then seeded onto OP9-DL1 with untransplanted CD45.2+ WT LSKs at a 1:1 
ratio on day 0.  (a) Relative contribution of cells and (c) percentage of 
preconditioned CD45.1+ WT LSKs at day 12 in culture.  Data	  represent	  the	  mean	  
+	  SEM,	  n	  =	  5	  observations	  per	  strain	  over	  2	  independent	  transplant	  experiments.	   
(b) T-cell differentiation kinetics and (d) percentage	   of	   CD45.1+	   preconditioned	  
WT	  LSKs	  differentiating	  into	  DN2	  stage	  at	  day	  6	  in	  culture.	  Data	  represent	  the	  
mean	   +	   SEM,	   n	   =	   10	   observations	   from	   WT	   and	   8	   from	   Nrf2-­/-­	   hosts	   over	   2	  
	  12	  
independent	   transplant	  experiments.	   	   (e - h) CD45.2+ WT or Nrf2-/- LSKs were 
preconditioned in CD45.1+ WT animals in vivo then seeded onto OP9-DL1 with 
untransplanted CD45.1+ WT LSKs at a 1:1 ratio at day 0.  (e) Relative 
contribution of cells and (g) percentage of preconditioned CD45.2+ WT	  or	  Nrf2-­/-­	  
LSKs at day 12 of culture. Data	  represent	  the	  mean	  +	  SEM,	  n	  =	  10	  observations	  
from	  WT	  and	  8	  from	  Nrf2-­/-­	  donors	  over	  2	  independent	  transplant	  experiments. 
(f) T-cell differentiation kinetics and (h) percentage	   of	   CD45.2+	   preconditioned	  
WT	   or	   Nrf2-­/-­	   LSKs	   differentiating	   into	   DN2	   stage	   at	   day	   6	   in	   culture.	   Data	  
represent	   the	   mean	   +	   SEM,	   n	   =	   9	   observations	   from	   WT	   and	   8	   from	   Nrf2-­/-­	  
donors	  over	  2	  independent	  transplant	  experiments.	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Nrf2 could be found at the transcript level in both LT-HSCs as well as their 
downstream MPPs (Figure 1.4, a), suggesting that despite their unaltered 
frequency in deficient animals (Figure 1.1, c), Nrf2 could act on this earliest 
haematopoietic population.  Consistent with our findings on the bulk LSK cells, 
we found a greater proportion of Nrf2-/- LT-HSCs expressed Ki-67 (Figure 1.4, b), 
indicating that more HSCs were undergoing proliferation.  Functionally, Nrf2-
deficient LT-HSCs differentiated more rapidly on OP9-DL1 culture than WT 
controls (Figure 1.4, c, d).  These data demonstrate that Nrf2 plays an important 
role in HSPC proliferation and differentiation starting at the LT-HSC stage.  
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Figure 1.4. Nrf2 Controls LT-HSC Proliferation and Differentiation  
(a) Expression of Nfe2l2 mRNA transcripts in sorted WT LT-HSC and MPP, 
presented relative to Actb expression.  Data represent the mean + SEM, n = 3 
independent experiments. (b) Expression of Ki-67 in WT and Nrf2-/- BM LT-HSCs, 
representative plot (left) and bar graph (right) showing mean + SEM of 4 animals 
per strain over 2 independent experiments.   (c) Differentiation of WT or Nrf2-/- 
LT-HSCs (d) percentage of LT-HSCs differentiating into DN2 stage at day 18 of 
OP9-DL1 co-culture system. Data represent the mean + SEM, n = 2 independent 
observations from WT and 3 from Nrf2-/- animals over 2 experiments.  
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Nrf2 Maintains HSC Quiescence and Self-Renewal 
Based on these findings, we hypothesised that Nrf2 functions as a negative 
regulator of cell cycle entry in HSCs, actively maintaining the balance between 
HSC quiescence and self-renewal.  As the synthesis of cyclin D is initiated during 
G1 phase, and its presence is required for the transition to S phase, we first 
assessed the level of cyclin D expression as an indirect measure of quiescence in 
the bone marrow.  We found a 2-fold increase in cyclin D1+ cells in the Nrf2-/- BM 
(Figure 1.5, a, b), and higher levels of cyclin D at the transcript level in purified 
Nrf2-/- LSKs (Figure 1.5, c).  Furthermore, by analyzing RNA and DNA contents 
using Pyronin Y and Hoeschst 33342, we found fewer LSKs from Nrf2-/- BM in the 
quiescent G0 state (Figure 1.5, d), and importantly also reduced proportion of the 
most primitive LT-HSCs in G0 stage (Figure 1.5, e).  These findings support our 
hypothesis that Nrf2 acts as a negative regulator of cell cycle progression, thereby 
maintaining HSC quiescence.  To further explore this phenomenon in vivo, we 
exploited the characteristic of 5-Fluorouracil (5-FU), which kills cycling cells and 
spares quiescent stem cells.  Following a single dose of 5-FU, we observed a 
profound reduction in the number of LT-HSCs in Nrf2-/- mice compared to WT 
controls (Figure 1.5, f).  These findings suggest that the HSC compartment of Nrf2 
deficient mice is considerably less quiescent than WT controls.  
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Figure 1.5. Nrf2 Maintains HSC Quiescence  
(a) Representative immunohistochemistry images and (b) Quantification of Cyclin 
D+ cells in WT and Nrf2-/- BM sections.  Data represent mean + SEM of 8 animals 
per strain.  (c) Expression of Ccnd1 mRNA transcripts in WT and Nrf2-/- LSKs, 
relative to Actb expression.  Data represent mean + SEM of 4 WT and 3 Nrf2-/- 
animals.  (d) Representative flow cytometric analysis (Left panel) showing cell 
cycle status of WT and Nrf2-/- LSKs and bar graph (Right panel) showing the 
percentage of cells in the quiescent G0 phase.  Data represent mean + SEM of 5 
WT and 6 Nrf2-/- animals.  (e) Representative flow cytometric analysis (Left panel) 
showing cell cycle status of WT and Nrf2-/- LT-HSCs and bar graph (Right panel) 
showing the percentage of cells in the quiescent G0 phase.  Data represent mean + 
SEM of 4 animals per strain.   
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Given the hyperproliferation of Nrf2-/- HSCs, coupled with the reduction of 
HSC quiescence, continued insult should lead to accelerated 
haematopoietic exhaustion.  Consistent with our hypothesis, Nrf2-/- mice 
challenged with sequential 5-FU treatment, died significantly earlier than 
WT controls (Figure 1.6, a).  To directly assess whether Nrf2 controls the 
self-renewal ability of HSCs, in addition to maintaining HSPC quiescence, 
we performed sequential CAFC assay in vitro and serial competitive 
transplantation in vivo.  In both the secondary plating and transplantation, 
we saw a dramatic reduction in the contribution of Nrf2-/- HSCs (Figure 
1.6, b, c).  Taken together, our data demonstrate that Nrf2 plays an 
important role in maintaining the balance between HSC quiescence and 
self-renewal.  
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Figure 1.6. Nrf2 Sustains HSC Self-renewal  
(a) Survival of WT and Nrf2-/- mice following sequential 5-FU treatment, n = 8 
animals per strain over 2 independent experiments.  (b) Bar graphs showing 
colony formation in serial CAFC assays, mean + SEM of 8 animals per strain over 
3 independent experiments.  (c) Equal numbers of donor CD45.2+ (WT or Nrf2-/-) 
and competitor CD45.1+ (WT) LSK cells from BM were serially transplanted into 
lethally irradiated CD45.1+ (WT) recipients.  Contribution of donor-derived 
(CD45.2+) BM LSKs was assessed 4 months after primary and secondary bone 
marrow transplants (BMT).  Data represent the mean + SEM of 12 recipients of 
WT and 14 recipients of Nrf2-/- donor cells in primary transplant and 9 recipients 
of WT and 10 recipients of Nrf2-/- donor cells in secondary transplant over 2 
independent experiments.  
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Nrf2 Governs HSPC Retention and Migration to the Bone Marrow Niche 
Interestingly, in the steady-state, Nrf2-/- mice displayed a significantly higher 
frequency and absolute number of HSPCs in the spleen (Figure 1.7, a).  Consistent 
with this finding, Nrf2-/- splenocytes gave rise to significantly more CFU-GM and 
BFU-E colonies in CFC assays, and sorted Nrf2-/- splenic LSKs mimicked their 
BM counterparts and once again differentiated more rapidly when co-cultured with 
OP9-DL1 stromal cells (Figure 1.7, a, b).  To address whether this increase in 
peripheral LSKs was due to a cell-intrinsic defect in HSPC retention, we generated 
chimeras with sorted CD45.2+ WT or Nrf2-/- LSKs transplanted into CD45.1+ WT 
hosts.  After 8 weeks following transplant, we found significantly fewer Nrf2-/- 
LSKs in the BM and drastically more in the periphery (Figure 1.7, d – g).  To 
explore the homing capacity, we labelled purified lineage-depleted (Lin-) BM cells 
from CD45.1+ WT and CD45.2+ WT or Nrf2-/- mice with fluorescent dyes, injected 
them into lethally irradiated WT recipients, and quantified the contribution of cells 
present in the recipient BM 18 hours after transplant by flow cytometry.  We 
observed that Nrf2-/- Lin- BM cells trafficked to the bone marrow niche less 
efficiently than CD45.2+ WT controls (Figure 1.7, h, i), implying that Nrf2 is 
required for efficient homing of BM cells.  To specifically examine the impact of 
Nrf2 on the homing of HSCs, we labelled and mixed WT and Nrf2-/- BM at 1:1 
ratio, and compared the engraftment efficiency of the LT-HSCs 16 hours after 
transplant.  Although present at equal numbers in the inoculum, Nrf2-/- LT-HSCs 
showed a significant impairment in BM engraftment, indicating a defect in their 
homing ability (Figure 1.7, j, k).  Collectively, these findings suggest that Nrf2 
governs the retention of HSCs and their homing to the BM niche.  
	  20	  
Figure 1.7. Nrf2 Governs HSPC Retention and Migration to BM Niche 
(a) Absolute number of LSK cells in untreated spleen; mean + SEM of 13 WT and 
14 Nrf2-/- animals over 4 independent experiments.  (b) Splenocytes were cultured 
in CFC conditions and colonies were scored for myeloid and erythroid lineages; 
mean + SEM of 9 WT and 8 Nrf2-/- animals over 2 independent experiments.  (c) 
LSK cells were isolated from spleen and co-cultured for 11 days with OP9-DL1 
stromal cells, representative plots of 2 independent experiments.  (d - g) CD45.2+ 
WT or Nrf2-/- LSKs were transplanted into lethally irradiated CD45.1+ WT 
recipients.  Retention in the BM niche was assessed 8 weeks post-BMT.  (d) 
Representative flow cytometric analysis and (e) quantification of WT or Nrf2-/- 
LSKs retained in the WT BM; mean + SEM of 10 recipients of WT and 8 recipients 
of Nrf2-/- LSKs over 2 independent experiments.  (f) Representative flow cytometric 
analysis and (g) quantification of WT or Nrf2-/- LSKs mobilised to the WT spleen; 
mean + SEM of 10 recipients of WT and 8 recipients of Nrf2-/- LSKs over 2 
independent experiments.  (h - i) Equal numbers of CFSE+ (CD45.1+ WT) and 
Violet+ (CD45.2+ WT or Nrf2-/-) Lin- BM cells were transplanted into lethally 
irradiated CD45.1+ WT recipients and BM content was assessed 18 hours post-
transplant.  Representative flow cytometric analysis (h) and bar graphs (i) of WT 
or Nrf2-/- Lin- BM cells.  Homing efficiency = absolute number of dye+ Lin- cells 
engrafted ÷ absolute number of dye+ Lin- cells transplanted; mean + SEM of 10 
recipients per strain over 2 independent experiments.  (j - k) Equal numbers of 
Violet+ (CD45.2+ WT) and CFSE+ (CD45.2+ Nrf2-/-) BM cells were transplanted 
into lethally irradiated CD45.2+ WT recipients, and content of LT-HSCs was 
assessed 16 hours post-transplant.  Representative flow cytometric analysis (j) and 
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bar graphs (k) showing the proportion of dye+ LT-HSCs in the pre-transplant mix 
(Left panel, pre-BMT) and in recipients 16 hours post-transplant (Right panel, 
post-BMT); mean + SEM of 16 recipients per strain over 3 independent 
experiments.  
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Nrf2 Mediates HSPC Function Through CXCR4 
In addition to its well-described role as a crucial chemokine receptor for HSPC 
homing and retention, there has been considerable interest recently in the role of 
CXCR4 signalling for its role in maintaining HSC quiescence 18-20.  Strikingly, our 
findings on the role of Nrf2 on HSC homing and quiescence closely mirrored the 
observations in Cxcr4-/- adult animals.  This directed us to investigate the 
interaction between Nrf2 and CXCR4.  Although there was no change in the 
expression of VCAM-1 (Figure 1.8, a, b), another key molecule for HSPC 
homing, we found a 2-fold reduction in CXCR4 expression in Nrf2-/- LSKs 
compared to WT controls (Figure 1.8, c, d), which again was observed as early as 
in LT-HSC stage (Figure 1.8, e, f).  This finding was functionally confirmed by 
performing in vitro transwell migration assays, where we found that Nrf2-/- LSKs 
migrated less efficiently towards CXCL12 at 6 hours (Figure 1.8, g), consistent 
with the reduced expression of CXCR4 caused by Nrf2-deficiency in HSPCs.   
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Figure 1.8.  Reduced CXCR4 Expression in Nrf2-/- HSPCs 
(a) Representative flow cytometric analysis and (b) bar graphs showing the 
proportion of sorted WT and Nrf2-/- BM LSK cells expressing VCAM-1.  Δ MFI 
(Mean fluorescence intensity) = (MFI of WT LSKs) - (MFI of Nrf2-/- LSKs).  Data 
represent the mean + SEM, n = 5 animals per strain.  c) Representative flow 
cytometric analysis and (d) bar graphs showing the proportion of sorted WT and 
Nrf2-/- BM LSK cells expressing CXCR4; mean + SEM of 4 animals per strain.  (e) 
Representative flow cytometric analysis and (f) bar graphs showing the proportion 
of sorted WT and Nrf2-/- BM LT-HSCs expressing CXCR4; mean + SEM of 6 
animals per strain.  (g) Percentage of LSK cells that migrated toward 
unconditioned media with (+) or without (-) supplementation of CXCL12 at 6 
hours of assays; mean + SEM of 6 observations per strain over 2 independent 
experiments.   
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To determine whether CXCR4 is a direct target of Nrf2, we scrutinised the 
promoter region of the mouse and human CXCR4 gene, and identified two 
putative conserved Nrf2 binding sites in the Cxcr4 promoter (Figure 1.9, a).  We 
cloned the Cxcr4 promoter from mouse genomic DNA into a dual luciferase 
reporter vector, and demonstrated that exogenous Nrf2 transactivated the minimal 
promoter region in vitro (Figure 1.9, b).  In addition, to assess whether 
endogenous Nrf2 binds to the Cxcr4 promoter in BM, we conducted chromatin 
immunoprecipitation assays.  We noted enrichment of both putative binding sites 
immunoprecipitated by Nrf2, confirming the physical interaction of endogenous 
Nrf2 and the Cxcr4 promoter in vivo (Figure 1.9, c).  Thus, Nrf2 directly binds to 
Cxcr4 promoter and activates its expression.  
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Figure 1.9.  Nrf2 Regulates Cxcr4 Promoter 
(a) Schematic diagram representing the regulatory region of Cxcr4 promoter.  The 
positions of potential transcription factor binding sites are noted (bp).  BS, 
putative Nrf2 Binding Site; TSS, Transcription Start Site.  (b) HEK293T cells were 
transfected with Cxcr4 promoter-driven luciferase reporter plasmids (covering -
0.5 kb from TSS), and luciferase activity was assessed 24 hours after transfection.  
Data represent the mean + SEM of 3 independent experiments.  (c) Chromatin 
bound DNA from WT BM was immunoprecipitated with a Nrf2-specific antibody 
or IgG control.  Quantitative PCR was performed using primers amplifying 
potential Nrf2 binding sites on Cxcr4 promoter.  Data represent the mean of 2 
independent experiments.  
 
 
 
	  26	  
Finally, we sought to examine whether dysregulation of CXCR4 expression 
contributed to the dual quiescence and migration defects observed in Nrf2-/- 
HSPCs.  Lentiviral overexpression of CXCR4 in Nrf2-/- LSK cells restored the 
homing ability of Nrf2-/- HSPCs in transwell migration assays (Figure 1.10, a, b), 
as well as rescued the phenotype of Nrf2-/- HSPCs in their differentiation kinetics 
on OP9-DL1 co-culture to a comparable pace with WT LSKs  (Figure 1.10, a, c).  
Taken together, these results suggest that Nrf2 controls multiple aspects of 
haematopoiesis at least partially through regulation of CXCR4 signalling.  
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Figure 1.10.  Nrf2 Mediates HSPC Functions Through CXCR4 
(a) Transduction efficiency of WT or Nrf2-/- LSKs with CXCR4-expressing vector 
(marked by expression of GFP) assessed 48 hours after transduction.  (b) 
Percentage of GFP-transduced or CXCR4-overexpressing WT and Nrf2-/- LSK 
cells migrated toward unconditioned media supplemented with CXCL12 at 6 hours 
of assays; mean + SEM of 5 independent experiments.  (c) Representative flow 
cytometric analysis showing differentiation of WT or Nrf2-/- LSKs, transduced with 
GFP-control or CXCR4-overexpressing vector, at day 11 of OP9-DL1 co-culture, 
reproducible in 3 independent experiments.   
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CHAPTER THREE 
Nrf2 Regulates T-cell Alloreactivity 
 
T cell activation promotes Nrf2 nuclear translocation and protein expression  
To define the biological significance of Nrf2 in T-cell alloreactivity, we first 
assessed the expression pattern of Nrf2 in activated T cells. We found that total 
cellular Nrf2 expression in T cells was significantly increased 24 hours after T cell 
receptor (TCR) stimulation in vitro with α-CD3/CD28 (Figure 2.1, a, b).  
Moreover, there was approximately a 2-fold induction in the nuclear fraction of 
Nrf2 upon T cell activation (Figure 2.1, a, c). We questioned whether this 
increased nuclear translocation corresponds to enhanced transcriptional activities 
of Nrf2. Surprisingly, the expression of the canonical Nrf2 antioxidant target genes 
Hmox1 and Nqo1 was not increased in activated T cells (Figure 2.1, d), implying 
that additional, non-canonical, nuclear Nrf2 functions may exist upon TCR 
ligation. We next examined the effects of T cell allo-activation in vivo on Nrf2 
activity. We used a well-established, fully MHC-mismatched murine allo-BMT 
model (B6  BALB/c) for its potential for strong allo-activation and for its utility 
in subsequent GVHD studies. Compared to their syngeneic controls, donor-derived 
T cells, specifically the CD4+ subsets, significantly upregulated their intracellular 
Nrf2 levels in the allogeneic setting (Figure 2.1, e). Taken together, these findings 
suggest a role for Nrf2 in T cell responses both in vitro and in vivo.  
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Figure 2.1.  T Cell Activation Promotes Nrf2 Nuclear Translocation and Protein 
Expression 
Representative immunofluorescent images (a) and quantification of cellular mean 
fluoresecent intensity (MFI) (b) and nuclear:cytopalsmic ratio (c) of Nrf2 (purple) 
in T cells stimulated with a-CD3/CD28 for 24 hrs. The nucleus is defined by DAPI 
staining (blue). (d) Expression of Hmox1 and Nqo1 mRNA transcripts in T cells 
stimulated with a-CD3/CD28 for 24 hrs. (e) WT B6 T-cell depleted (TCD) BM and 
T cells were transplanted into lethally irradiated B6 (Syn-BMT) or BALB/c (Allo-
BMT) recipients. Flow cytometric analysis on the intracellular levels of Nrf2 
within donor T cells was performed using recipient spleens on Day 14 after BMT. 
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Nrf2-/- donor T cells induces less GVHD mortality and morbidity 
To specifically determine whether Nrf2 contributes to T-cell alloreactivity, we 
isolated Nrf2-/- splenic donor T cells and observed their ability to mediate acute 
GVHD in MHC-mismatched recipients (B6  BALB/c).  Importantly, wildetype 
(WT) and Nrf2-/- spleens displayed comparable total numbers and equally diverse 
TCR repertoire of both CD4+ and CD8+ T cell subsets under steady-state (Figure 
2.2, a, b). Consistent with our hypothesis, MHC-mismatched recipients of Nrf2-/- 
donor T cells benefited from a significantly greater survival rate compared with 
recipients of WT T cells (Figure 2.2, c). Additionally, Nrf2-/- donor T cells led to 
significantly lower clinical GVHD scores and weight loss, resulting in an overall 
less GVHD morbidity in allo-BMT recipients (Figure 2.2, d, e). Moreover, these 
findings were recapitulated when a less fulminant, yet more clinically relevant, 
minor histocompatibility antigen (mHA)-mismatched model (B6  LP) was used 
(Figure 2.2, f - h), indicating a critical role of Nrf2 in general rather than model-
specific GVHD pathogenesis.  
Figure 2.2.  Nrf2-/- T Cells Induces Less GVHD Mortality and Morbidity 
(a - b) WT and Nrf2-/- splenocytes under steady-state were examined using flow 
cytometry for (a) T cell subset enumeration and (b) TCR Vb family repertoire. (c - 
d) Lethally irradiated BALB/c recipients received WT B6 TCD-BM alone, or with 
0.5 x 106 B6 WT or Nrf2-/- T cells were monitored daily for (c) survival and weekly 
for (d) GVHD clinical scores and (e) weight loss. (f - h) Lethally irradiated LP 
recipients received WT B6 TCD-BM alone, or with 2 x 106 B6 WT or Nrf2-/- T cells 
were monitored daily for (f) survival and weekly for (g) GVHD clinical scores and 
(h) weight loss.  Data represent the mean + SEM.  
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Nrf2 activity in allo-T cells contributes to hepatic, intestinal, and thymic 
GVHD  
Acute GVHD results from activated donor allo-T cells recognizing alloantigens 
and destructing vital recipient organs, classically the triad of skin, liver, and 
gastrointestinal (GI) tract. While isolated skin GVHD does not contribute to 
mortality and the incidence of hepatic GVHD has become infrequent, GI GVHD 
has dominated the most severe and life-threatening cases following allo-BMT21-23. 
To determine whether the improved clinical outcomes of Nrf2-/- T-cell recipients 
could be attributed to reduced damage to specific GVHD target organs, we 
performed a semiquantitative histopathologic analysis of tissue samples in a 
blinded fashion after MHC-mismatched transplantation. In keeping with our 
hypothesis, recipients of Nrf2-/- T cells showed markedly reduced composite 
GVHD pathology scores, including liver, small bowel, and large bowel (Figure 
2.3, a). Interestingly, however, Nrf2-deficiency in donor T cells did not 
significantly impact on the development of cutaneous GVHD, as indicated by the 
equivalent numbers of apoptotic keratinocytes in epidermis of WT and Nrf2-/- T-
cell recipients (Figure 2.3, b).  Additionally, donor allo-T cells mediate thymic 
GVHD, which leads to profound T cell deficiency and restricted repertoire 
following allo-BMT24-27. We discovered an increase in the overall thymic 
cellularity and the percentage of CD4+CD8+ double-positive (DP) thymocytes 
using flow cytometric analysis, reflecting significantly less thymic damage 
associated with GVHD, in the Nrf2-/- T cell recipients following allo-BMT (Figure 
2.3, c, d). In short, these findings suggest that Nrf2 activity in donor T cells 
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contributes to the development of hepatic, GI, and thymic but not cutaneous 
GVHD.  
 
Figure 2.3.  Nrf2-/- Donor T Cells Results in Less Hepatic, Intestinal, and 
Thymic GVHD 
Lethally irradiated BALB/c recipients received B6 WT TCD-BM and 0.5 x 106 B6 
WT or Nrf2-/- T cells. GVHD target organs of recipients were analyzed on day 14. 
(a) H&E-stained slides of liver, small intestine, and large intestine were scored for 
histopathologic damage. (b) H&E-stained slides of skin were assessed for the 
number of apoptotc keratinocytes per cm of epidermis. (c - d) Flow cytometric 
analysis of thymic damage with (c) representative dot plots showing percentage 
and (d) enumeration of total CD4+CD8+ double-positive (DP) thymocytes.    
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Nrf2-/- donor T cells display intact proliferation, activation, and apoptosis 
during the early phase of alloreactivity 
Before infiltrating the target organs of recipients and as early as 12 hours following 
transfer, donor allo-T cells specifically trafficked to secondary lymphoid tissues 
where they undergo activation and proliferation upon exposure to alloantigen28-31. 
To assess whether the diminished GVHD activity of Nrf2-/- allo-T was due to 
defective early alloactivation, we transplanted CFSE-labeled T cells in MHC-
mismatched recipients.  In order to examine the extent to the proliferation of donor 
T cells that had undergone during alloactivation, we measured the rounds of CFSE 
dilution 96 hours following transfer using flow cytometry.  Surprisingly, Nrf2-/- T 
cells displayed equivalent ability of alloantigen-induced proliferation, as indicated 
by the percentages of undivided and highly-proliferated fractions (CFSElow) as 
well as the total numbers of highly-proliferated cells in recipient spleen (Figure 
2.4, a, b). Nrf2-/- T cells also showed comparable activation, as determined by 
upregulation of CD25 and CD44 as well as downregulation of CD62L on the 
highly-proliferated alloactivated population (Figure 2.4, d). Additionally, T cells 
may undergo activation-induced cell death (AICD), a physiologically important 
process to control clonal expansion of activated T cells and contributes to 
downregulation of immune responses32,33.  Nrf2-/- donor T cells demonstrated 
similar degree of apoptosis induced by alloactivation, as evidenced by the level of 
Annexin-V expression in highly-proliferated fractions (Figure 2.4, c).  
Interestingly, although Nrf2-/- T cells showed equivalent proliferation and ACID 
during the initial alloactivation phase, we found a significantly greater number of 
Nrf2-/- CD8+ donor T cells in recipient spleens on days 7 and 14. Nonetheless, 
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these data suggest that proliferation, activation and apoptosis during the early 
phase of alloreactivity were unlikely to be contributory mechanisms for the better 
GVHD clinical outcomes induced by Nrf2-/- allo-T cells (Figure 2.5, a).   
Figure 2.4. Nrf2-/- T Cells Display Intact Proliferation, Activation, and 
Survival 
Lethally irradiated BALB/c recipients were transplanted with 5 x 106 CFSE-
labeled B6 WT or Nrf2-/- T cells. Recepient spleens were analyzed 96 hours after 
transplant by flow cytometry for CFSE dilution. (a) Comparable CFSE histogram 
overlays and (b) equivalent total numbers of CFSElow WT versus Nrf2-/- donor T 
cells, gated on H-2Kb+ events. (c) Similar expression of the apoptotic marker 
Annexin-V and (d) equivalent upregulation of the activation markers CD25, CD44 
and downregulation of CD62L on WT versus Nrf2-/- donor allo-T cells, gated on 
H-2Kb+CFSElow populations.  
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Nrf2-/- donor T cells display decreased intestinal infiltration and LPAM-1 
expression 
While the levels of early activation and proliferation are comparable across all 
priming sites, different secondary lymphoid organs imprint distinct homing 
receptor phenotypes and thus specify the infiltration to GVHD target organs of 
evolving donor allo-T cells30,34-39.  Specifically, antigen presenting cells (APCs) 
within mesenteric lymph nodes (MLNs) are known to play a pivotal role in 
upregulating gut-homing receptors on donor allo-T cells.  Given the reduced 
hepatic and intestinal GVHD pathology observed in Nrf2-/- allo-T cell recipients, 
we questioned whether Nrf2 modulates allo-T cell trafficking to intestines. 
Importantly, we found equivalent numbers of donor T cells in recipient MLNs on 
days 7 and 14, indicating intact migration of Nrf2-/- donor T cells to secondary 
lymphoid organs (Figure 2.5, b). However, we observed defective trafficking of 
these cells into intestinal tissues, as demonstrated by a decrease in the lymphocytic 
infiltrate within the small intestine and the large intestine of Nrf2-/- allo-T cell 
recipients (Figure 2.5, c).  We further examined the expression of gut-specific 
homing molecules of donor allo-T cells, including LPAM-1 (homing to small 
intestine, large intestine, and liver) and CCR9 (homing to small intestine). While 
we observed no difference in CCR9 expression, we saw a small but statistically 
significant decrease in the expression of LPAM-1 in Nrf2-/- donor CD8+ T cells in 
recipient spleens (Figure 2.5, d, e). Collectively, these data suggest that defective 
upregulation of LPAM by donor CD8+ T cells possibly underlies the attenuated 
GVHD severity caused by Nrf2-/- allo-T cells. 
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Figure 2.5. Nrf2-/- Donor T Cells Display Decreased Intestinal Infiltration and 
LPAM-1 Expression 
Lethally irradiated BALB/c recipients were transplanted with WT B6 TCD-BM and 
0.5 x 106 B6 WT or Nrf2-/- T cells. Recipient organs were analyzed on day 14. (a) 
Spleens and (b) MLNs were analyzed for donor CD4 and CD8 T cells using flow 
cytometry. (c) H&E-stained slides of small and large intestines were scored for 
lymphocyte infitration. (d – e) Splenocytes were analyzed for the percentage of (d) 
LPAM-1 and (e) CCR9 expression in donor T cells.   
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Abrogation of GVHD in Nrf2-/- allo-T cell recipients is associated with a 
greater proportion of donor-derived CD4+ Helios+ regulatory T cells  
We next sought to evaluate the functional alterations of CD4+ allo-T cells as a 
result of Nrf2-deficiency. We proposed that Nrf2 may contribute to distinct 
compartmentalization in helper T helper cell (Th) subsets.  Consistent with our 
hypothesis, analysis of intracellular levels of signature transcription factors 
required for different Th subsets revealed a significantly greater percentage and 
absolute number of donor-derived regulatory T cells (Tregs) in the spleen of Nrf2-/- 
allo-T cell recipient on day 7 post transplant (Figure 2.6, a - c). Tregs have been 
broadly defined into two main categories, thymus-derived natural Tregs (nTregs) 
and peripherally adapted induced Tregs (iTregs), both important in maintaining 
immune tolerance.  To determine if Nrf2 regulates peripheral generation of iTregs, 
we activated naïve CD4+ T cells isolated from steady-state spleens under Treg 
differentiating cytokine conditions in vitro. Refuting our hypothesis, we observed 
an equivalent fraction of WT and Nrf2-/- CD4+ T cells polarized towards Tregs in 
vitro (Figure 2.7, a, b).  
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Figure 2.6. Nrf2 Ablation Alters Donor CD4+ T Cell Compartmentalization 
Lethally irradiated BALB/c recipients were transplanted with WT B6 TCD-BM and 
0.5 x 106 B6 WT or Nrf2-/- T cells. Recipient spleens were stained for intracellular 
transcription factors for flow cytometric analysis of donor CD4+ T cell subsets on 
day 7. (a) Percentage of donor CD4+ T cell subsets defined by the expression of T-
bet (Th1), GATA-3 (Th2), RORgt (Th17) and Foxp3 with CD25 (Treg). (b) 
Representative flow cytometric dot plots showing the frequency of WT and Nrf2-/- 
donor Tregs within CD4+ T cells. (c) Bar graphs showing absolute numbers of WT 
and Nrf2-/- donor Tregs.  
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Figure 2.7. Nrf2 is Dispensible for Induction of Tregs in vitro   
Naïve CD4+ T cells isolated from steady-state WT or Nrf2-/- mice were cultured in 
non-polarizing (α-CD3/CD28 + IL-2) or Treg-inducing (+TGFb) conditions. (a) 
Representative flow cytometric analysis showing percentage of induced Tregs on 
day 5. (b) Percentages of CD4+ T cells polarized to Treg in Treg-inducing 
conditions on day 1, 3, and 5.    
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It has been reported that the Ikaros transcription factor family member Helios and 
the membrane-bound tyrosine kinase receptor Neuropilin-1 (Nrp-1) are highly 
enriched in nTregs and thus their expression may serve as markers to discriminate 
nTregs from iTregs40. Interestingly, while we did not detect any differences in 
Nrp-1 expression (data not shown), we saw a significantly greater percentage of 
donor-derived Tregs expressing Helios in Nrf2-/- allo-T recipients on day 7 after 
BMT (Figure 2.8, a, b).  Moreover, the amount of Helios expressed on a per cell 
basis was also significantly higher in donor Nrf2-/- Tregs compared to WT Tregs 
after allo-BMT (Figure 2.8, a, b). Notably, we did not observe any baseline 
differences in the total number or percentage of Tregs, and we found equally large 
fraction and high cellular expression of Helios within Treg populations in the 
donor inoculum prior to transplantation (Figure 2.9, a - f).  
 
Additionally, recent literature suggests that Helios is required to stabilize the 
expression of the transcription factor FoxP3 and, thus by extension, the abundance 
and inhibitory activity of Treg cells in inflammatory settings41,42. In accordance 
with this notion, we identified an increase in the cellular FoxP3 protein expression 
within donor Nrf2-/- Tregs in the MHC-mismatched recipients, implying more 
stable suppression from Nrf2-/- Tregs on the alloreactive response41 (Figure 2.8, c, 
d). 
 
To further elucidate the biological significance of Nrf2 function on nTreg cells, we 
removed CD4+CD25+ putative Tregs from the donor inoculum and transplanted 
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only conventional T cells in MHC-mismatched recipients. We found that the 
survival advantage with Nrf2-/- allo-T cells during GVHD was completely 
abolished when Tregs were absent in the donor inoculum at the time of transplant 
(Figure 2.8, e).  Taken these together, we conclude that Nrf2 function in donor T 
cells serves to undermine the stability of Tregs present in the graft during allo-
BMT, most likely through downregulation of Helios expression of nTregs.   
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Figure 2.8. Abrogation of GVHD in Nrf2-/- allo-T cell recipients is associated 
with a greater proportion of donor-derived CD4+ Helios+ Tregs 
(a – d) Lethally irradiated BALB/c recipients were transplanted with WT B6 TCD-
BM and 0.5 x 106 B6 WT or Nrf2-/- T cells. Recipient spleens were analyzed on day 
7 for intracellular expression of (a, b) Helios and (c, d) Foxp3 in donor-derived 
Tregs. (e) Lethally irradiated BALB/c recipients transplanted with WT B6 TCD-
BM alone or with a total of 0.5 x 106 Treg (CD4+CD25+)-depleted B6 WT or Nrf2-
/-conventional CD4 and CD8 T cells (Tcon) were monitored daily for survival.  
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Figure 2.9. WT and Nrf2-/- Tregs under steady-state do not differ before 
transplantation      
WT and Nrf2-/- splenocytes under steady-state were examined using flow cytometry 
for (a) total number of Treg per spleen, (b) percentage of Treg within CD4+ T 
cells, (c) mean fluorescence intensity of Foxp3 within Treg, (d) total number of 
Helios+ Tregs (e) percentage of Tregs expressing Helios, and (f) mean 
fluorescence intensity of Helios within Treg. 
 
Nrf2-/- donor CD8+ T cell showed intact cytotoxicity and GVT capacity 
We next sought to explore the role of Nrf2 on CD8+ T cell function independently 
from its effect on CD4+ T cells. To this end, we first activated naïve CD8+ T cells 
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isolated from steady-state spleens with TCR ligation in vitro, and examined their 
cytolytic capacity against a hematologic tumor bearing MHC-mismatched 
alloantigen (A20, murine B-cell lymphoma). Nrf2-/- CD8+ T cells displayed 
preserved specific killing ability in vitro, as measured by the comparable degree of 
chromium-51 (51Cr) released from the pre-labeled tumor target cells after co-
culture (Figure 2.10, a). To directly assess the cytotoxicity against alloantigen in 
an in vivo model as well as to maintain CD4+ help for CD8+ T-cell alloreactivity, 
we transplanted WT CD4 T cells mixed with WT or Nrf2-/- CD8+ T cells at a 
physiologic ratio (2:1) into MHC-mismatched recipients43,44, which were 
subsequently challenged with fluorescently labeled allogeneic target cells mixed 
with control syngenic cells at 1:1 ratio on day 7 after allo-BMT45,46 (Figure 2.10, 
b). Compared with BM only recipients, recipients of WT and Nrf2-/- CD8+ T cells 
demonstrated equally efficient elimination of allogenic targets, consistent with our 
in vitro findings (Figure 2.10, a).  
 
Furthermore, to determine the clinical significance of preserved cytotoxicity of 
Nrf2-/- CD8+ T cells on GVHD pathogenesis, we followed the clinical course of 
MHC-mismatched allo-BMT recipients transplanted with WT CD4+ T cells mixed 
with WT or Nrf2-/- CD8+ T cells.  As expected, WT and Nrf2-/- CD8+ allo-T cells 
resulted in equally high mortality when transplanted with WT CD4+ T cells 
(Figure 2.10, c). Importantly, we saw a significant reduction in mortality when 
Nrf2-/- CD4+ and WT CD8+ allo-T cells were transplanted, further supporting the 
notion that Nrf2 predominately regulates CD4+ and is dispensable for CD8+ T-cell 
alloreactivity.  
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Finally, we sought to determine the impact of Nrf2 deficiency on the GVT activity 
of allo-T cells in a well-established in vivo model: B6  BALB/c with the A20 
lymphoma cells.  Using bioluminescent imaging (BLI), we were able to quantify 
tumor burden of established A20-TGL cell line that constitutively expresses firefly 
luciferase47. Compared with BM only recipients that rapidly developed tumor 
growth, recipients of Nrf2-/- T cells eradicated tumor as effectively as the WT T 
cells (Figure 2.10, d, e). With their diminished alloreactivity yet preserved tumor 
killing capability, Nrf2-/- T cells gave rise to an overall better survival in their allo-
BMT recipients compared to WT T cells (Figure 2.10, f).  
 
Figure 2.10. Nrf2 Is Dispensible for Donor CD8+ T-Cell Cytotoxicity and GVT 
Capacity 
(a) In vitro cytotoxicity assay. WT and Nrf2-/- CD8+ T cells isolated from steady-
state spleens were pre-activated with α-CD3/CD28 in vitro for 72 hours followed 
by incubation with 51Cr-labeled allogeneic A20 tumor target cells for 18-19 hours. 
(b) In vivo cytotoxicity assay. Lethally irradiated BALB/c recipients were 
transplanted with WT B6 TCD-BM and a total of 0.5 x 106 T cells composed of B6 
WT CD4+T cells mixed with WT or Nrf2-/- CD8+ T cells at 2:1 ratio. On day 7, 
recipients were challegend with a 1:1 infusion of CFSE-labled BALB/c allogeniec 
and PKH26-labeled B6 syngeneic control targets, and elimination of targets was 
assessed in the spleen by flow cytometry 4 hours after challenge. (c) Lethally 
irradiated BALB/c recipients were transplanted with WT B6 TCD-BM alone or 
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with a total of 0.5 x 106 T cells composed of B6 WT vs Nrf2-/- CD4+and CD8+ T 
cells mixed at 2:1 ratio. Recipients were minitored daily for mortality. (d - e) 
Lethally irradiated BALB/c recipients transplanted with WT B6 TCD-BM alone or 
with 0.5 x 106 WT or Nrf2-/- T cells were challenged with 0.5 x 106 A20-TGL. The 
whole-body distribution of tumor burden was tracked weekly using bioluminescent 
signal intensity. (d) Representative bioluminescent images showing pseudocolor 
images superimposed on conventional phographs. (e) Tumor burden in mice 
quantified as biolominescent image flux. (f) Lethally irradiated BALB/c recipients 
transplanted with WT B6 TCD-BM alone or with 0.5 x 106 WT or Nrf2-/- T cells 
were challenged with 0.5 x 106 A20-TGL. Recipients were minitored daily for 
mortality.  
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CHAPTER FIVE 
Discussion 
 
Nrf2	  Regulates	  HSC	  Function	  
Although Nrf2 has previously been reported to be dispensable for erythropoiesis 
and megakaryocyte differentiation 48-50, here we saw that it has a critical role in 
maintaining HSC function through its impacts on quiescence and self-renewal and, 
by extension, differentiation.  Consistent with previous observations, we found that 
Nrf2 did not appear to control lineage specification, as Nrf2-/- HSPCs displayed 
typical myeloid and lymphoid commitment.  Rather, our data argue that Nrf2 
functions as a master regulator of the main modalities of HSC function.  Not only 
do we show that Nrf2 can regulate the balance between quiescence and 
proliferation, but also between self-renewal and differentiation, as well as homing 
and retention of HSCs in the BM niche.  This firmly establishes an important role 
for Nrf2 in the most primitive haematopoietic compartment.  Moreover, our studies 
suggest that Nrf2 exerts its influence, at least in part, through direct regulation of 
CXCR4 expression.  Importantly, previous studies have shown that among the cell 
cycle regulators investigated, cyclin D1 was singularly upregulated in Cxcr4-/- 
LSKs20, consistent with our findings that cyclin D1 was upregulated in Nrf2-/- 
HSPCs. 
 
There is increasing evidence that maintaining intracellular ROS at its basal level is 
necessary for HSC quiescence 51-55.  The most widely studied transcription factor 
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linking the ROS pathway to HSC quiescence and self-renewal are the FOXO 
(Forkhead O) proteins, which are important downstream effectors of the 
insulin/IGF-1 like signalling (ISS) pathway.  Intriguingly, recent studies suggest 
that ISS not only inhibits DAF-16, the C. elegans homologue of FOXO, but also 
directly suppresses SKN-1, the C. elegans homologue of Nrf2, in aging 56.  There 
is also mounting evidence that the ISS and ROS signalling pathways cross-talk in 
the regulation of aging 57.  Interestingly, groups studying FOXO-deficient HSCs 
have found a similar phenotype to the one we describe here, alluding to the 
possibility that Nrf2 functions in parallel to the FOXO proteins as a downstream 
target of the PI3K-Akt pathway.  Future research to validate the involvement of 
Nrf2 in the ISS pathway in mammalian models could be of considerable interest in 
understanding HSC aging 58.   
 
Finally, a recent study has demonstrated a similar negative regulatory role for Nrf2 
in intestinal stem cell proliferation 59.  Considering that Nrf2 is ubiquitously 
expressed, and stem cells and their progenitors are critical to the maintenance and 
function of various tissues, these findings indicate that Nrf2 serves as a master 
regulator of stem cell integrity and longevity in adult tissues.  Future research into 
understanding and manipulating Nrf2 in tissue-specific stem cells and their niches 
may provide insights and innovative approaches to the field of regenerative 
medicine. 
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Nrf2	  Regulates	  T-­cell	  Alloreactivity	  
Allo-­‐BMT	   represents	   a	   curative	   therapy	   for	   a	   variety	   of	   hematologic	  malignancies	   and	   can	   even	   contribute	   to	   the	   clearance	   of	   remnant	  malignancies	   through	   GVT	   reactions.	   	   Understanding	   and	   dissecting	   the	  undesired	  GVHD	  and	  beneficial	  GVT	  activities	  of	  allo-­‐T	  cells	  is	  imperative	  for	  optimizing	   its	   therapeutic	   use	   by	   improving	   clinical	   outcomes	   of	   BMT	  recipients.	   	   In	   this	   study,	   we	   identified	   that	   Nrf2	   within	   donor	   T	   cells	  contributes	   significantly	   to	   the	   GVHD	   activity,	   but	   is	   dispensable	   for	   GVT	  actions.	   In	   the	   absence	   of	   Nrf2	   activation,	   acute	   GVHD	   is	   attenuated	   by	   the	  promotion	   of	   Helios+	   nTregs,	   while	   GVT	   is	   preserved	   due	   to	   intact	   CD8+	  cytotoxicity.	  	  
	  
Nrf2	  has	  been	  reported	  to	  modulate	  inflammation	  in	  different	  disease	  model,	  in	  which	  Nrf2-­/-­	  mice	  demonstrated	  increased	  susceptibility	  to	  experimentally	  induced	  sepsis,	  EAE,	  hepatitis,	  and	  asthma.	  However,	  it	  is	  clear	  that	  this	  is	  not	  its	   role	   in	   GVHD,	   as	   evidenced	   by	   our	   findings	   of	   reduced	   GVHD	  mortality,	  morbidity	   and	   pathology	   in	   the	   absence	   of	   Nrf2	   activity.	   One	   possible	  explanation	   for	   the	   contrasting	   role	   of	   Nrf2	   is	   the	   physiological	   differences	  among	  the	  models	  tested.	  Moreover,	  given	  the	  ubiquitous	  nature	  and	  thus	  the	  multiple	  potential	   targets	  of	  Nrf2,	  direct	   induction	  of	   inflammation	   in	  global	  
Nrf2-­/-­	  mice	  may	  obscure	   the	   specific	   effects	  of	  Nrf2	  activity	   in	  different	   cell	  subsets.	  Our	  study	  established	  the	  pro-­‐inflammatory	  effects	  of	  Nrf2	  signaling	  specifically	  within	  donor	  T	  cells	  by	  directly	  studying	  purified	  Nrf2-­/-­	  T	  cells	  in	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a	  MHC-­‐mismatched	  BMT	  model.	  Furthermore,	  the	  survival	  advantage	  seen	  in	  
Nrf2-­/-­	   T	   cell	   recipients	  was	  even	  greater	   in	   a	  more	   clinically	   relevant	  mHA-­‐mismatched	   model,	   further	   emphasizing	   the	   critical	   role	   of	   Nrf2	   in	   T-­‐cell	  alloreactivity	  and	  the	  clinical	  applicability	  of	  Nrf2	  abrogation	  in	  the	  transplant	  setting.	  	  
	  
Earlier	  studies	  specifically	  assessing	  the	  role	  of	  Nrf2	  within	  T	  cells	  focused	  on	  the	   effects	   of	   Nrf2	   activation	   in	   the	   cytokine	   production	   of	   CD4+	   subsets	   in	  
vitro	  and	  found	  conflicting	  results14-­‐16.	  Yet	  a	  major	  limitation	  of	  these	  studies	  is	   the	   reliance	   of	   electrophilic	   compounds	   that	   target	   multiple	   pathways.	  Although	   the	   synthetic	   antioxidant	   tert-­‐butylhydroquinone	   (tBHQ),	   for	  example,	  was	  commonly	  used	  to	  activate	  Nrf2	  in	  vitro	   in	  these	  studies,	  it	  has	  also	  been	  reported	  to	  activate	  PI3K-­‐Akt	  pathway	  and	  inhibit	  FoxO3a	  activity	  in	  other	  cell	  types60-­‐62.	  One	  group	  observed	  an	  increase	  in	  Nrf2	  expression	  as	  well	   as	   the	   transcripts	  of	   its	   classic	  antioxidant	   target	  genes	  when	  human	  T	  cells	   from	   healthy	   donors	   were	   activated	   in	   vitro15.	   However,	   this	   process	  seems	   to	   be	   independent	   from	   the	   oxidative	   stress,	   as	   the	   potent	   reducing	  agent	  N-­‐acetylcysteine	   (NAC),	   known	   to	   prevent	   oxidative	   stress-­‐dependent	  activation	   of	   Nrf2,	   failed	   to	   inhibit	   the	   induction	   of	   Nrf2	   expression	   in	  activated	  T	  cells	  in	  the	  same	  study15.	  We	  similarly	  found	  an	  increased	  protein	  level	  and	  nuclear	  translocation	  of	  Nrf2,	  yet	  we	  did	  not	  observe	  an	  increase	  in	  its	  canonical	  antioxidant	  target	  genes	  in	  activated	  WT	  murine	  T	  cells	  in	  vitro.	  Nonetheless,	   these	   findings	   suggest	   a	   non-­‐canonical	   Nrf2	   pathway,	   either	  upstream	   and/or	   downstream,	   may	   exist	   during	   T	   cell	   activation.	   One	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possible	   explanation	   is	   that	   the	   effects	   of	   Nrf2	   activation	   on	   its	   canonical	  versus	  non-­‐canonical	  targets	  are	  relative	  rather	  than	  absolute,	  and	  it	  may	  be	  dependent	  on	  TCR	  signal	  strength	  rather	  than	  oxidative	  stress.	  	  
	  
Additionally,	   we	   demonstrated	   here	   that	   alloactivation	   in	   vivo	   enhanced	  intracellular	   level	   of	   Nrf2	   in	   donor-­‐T	   cells,	   namely	   within	   the	   CD4+	   subset,	  reiterating	   the	   biological	   significance	   of	   Nrf2	   in	   CD4+	   T-­‐cell	   alloreactivity.	  However,	  this	  upregulation	  of	  Nrf2	  during	  allo-­‐BMT	  is	  not	  required	  for	  initial	  alloactivation,	   since	   Nrf2-­/-­	   donor	   T	   cells	   displayed	   intact	   proliferation,	  activation	   and	   apoptosis	   during	   early	   phase	   of	   alloreactvity.	   	   Instead,	   Nrf2	  exerts	   its	   effect	   during	   the	   expansion	   and	   target	   organ	   infiltration	   phase	   of	  acute	   GVHD,	   in	   which	   an	   increase	   in	   Tregs	   was	   seen	   in	   Nrf2-­/-­	   allo-­‐T	   cell	  recipients	  on	  day	  7	  post	  transplantation.	  	  Furthermore,	  we	  demonstrated	  here	  that	  this	  increase	  in	  Treg	  was	  due	  to	  stabilization	  and/or	  increased	  expansion	  of	   nTregs	   present	   in	   the	   inoculum	   that	   were	   unleashed	   from	   Nrf2	   and	   its	  proinflammatory	   property.	   This	  was	   evidenced	   by:	   1)	   the	   disappearance	   of	  the	   survival	   advantage	   of	   Nrf2-­/-­	   allo-­‐T	   recipients	   when	   putative	   Treg	   was	  removed	   from	   the	   graft	   before	   transplant;	   and	   (2)	   the	   relative	   increase	   in	  Helios	   expression,	   a	   marker	   for	   nTreg	   and	   critical	   for	   FoxP3	   stability,	   in	  donor-­‐derived	   Nrf2-­/-­	   Tregs	   only	   after	   but	   not	   before	   transplant.	   This	  augmentation	  in	  Treg	  in	  the	  absence	  of	  Nrf2,	  whether	  preceding	  or	  following	  it,	  is	  associated	  with	  reduced	  systemic	  inflammation	  after	  allo-­‐BMT,	  as	  shown	  by	   the	   ameliorated	  GVHD-­‐induced	  hepatic,	   intestinal,	   and	   thymic	  damage	   in	  
Nrf2-­/-­	  donor	  T	  cell	  recipients.	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Critical	  for	  their	  potential	  translation	  into	  improved	  allo-­‐BMT	  strategies,	  Nrf2-­
/-­	  donor	  T	   cells	   retained	   their	  GVT	  ability	   against	   hematologic	  malignancies.	  We	   demonstrated	   here	   that	  Nrf2-­/-­	   donor	   CD8+	   T	   preserved	   high	   quality	   of	  killing	   and	   antitumor	   activity,	   and	   a	   greater	   quantity	   of	   CD8+	   counts	  accumulating	   in	   the	   spleen	   of	   Nrf2-­/-­	   allo-­‐T	   cell	   recipients.	   One	   likely	  contributory	   mechanism	   is	   the	   defective	   upregulation	   of	   LPAM-­‐1	   in	   Nrf2-­/-­	  CD8	  T	  cells,	  possibly	  secondary	  to	  suppression	  from	  increased	  nTregs	  on	  APC	  priming,	  restrained	  them	  from	  infiltrating	  and	  damaging	  GVHD	  target	  organs	  and	   trapped	   them	   in	   the	   secondary	   lymphoid	   organs	   where	  lymphohematopoietic	  tumor	  cells	  like	  A20	  resides.	  Nrf2-­/-­	  donor	  CD8+	  T	  cells	  also	  possess	  a	  higher	  homeostatic	  proliferative	  potential	  under	   lymphopenic	  environement	  (data	  not	  shown),	  further	  contributing	  to	  increased	  circulating	  
Nrf2-­/-­	  donor	  CD8+	  T	  cells	  fully	  capable	  of	  combating	  liquid	  cancer.	  Moreover,	  our	   group	   has	   previously	   shown	   that,	   T	   cells	   lacking	   functional	   LPAM-­‐1	  receptors	  as	  a	   result	  of	  β7	  subunit	  deficiency	  actually	  have	  enhanced	   tumor	  clearance	   ability	   while	   causing	   less	   acute	   GVHD	   in	   their	   MHC-­‐mismatched	  recipients63,64.	   	   Furthermore,	   donor	  Tregs	   have	   previously	   been	   reported	   to	  be	  dispensable	   for	  GVT	  activity	  while	   inhibiting	  GVHD	  after	  allo-­‐BMT44.	   It	   is	  also	   important	   to	   remember	   that,	   in	   addition	   to	   GVHD	   suppression,	   donor	  Tregs	  (also	  CD8)	  have	  previously	  been	  shown	  to	  promote	  hematopoetic	  stem	  and	   progenitor	   cells	   (HSPC)	   engraftment	   as	   well	   as	   enhance	   immune	  reconstitution65,66.	   Last	   but	   not	   the	   least,	   mounting	   evidence	   suggests	   that	  Nrf2	   confers	   proliferation,	   survival	   and	   chemoresistance	   in	   various	   tumors	  including	   hematologic	   cancers9,11,12.	   Collectively,	   these	   findings	   support	   for	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developing	  new	  therapies	  directed	  toward	  the	  Nrf2	  pathway	  as	  an	  antitumor	  adjuvant	  and	  a	  strategy	  to	  prevent	  GVHD	  in	  patients	  undergoing	  allo-­‐BMT.	  	  
	  
In	   the	   second	   part	   of	   the	   dissertation,	   we	   show	   for	   the	   first	   time	   a	  comprehensive	   analysis	   of	   the	   role	   of	   Nrf2	   in	   T	   cell	   function	   in	   vivo.	   We	  present	  here	  that	  inhibition	  of	  Nrf2	  activity	  in	  donor	  T	  cells	  ameliorates	  GVHD	  severity	  without	  compromising	  GVT	  activity.	  Our	  findings	  not	  only	  shed	  light	  on	   the	   biological	   significance	   of	   Nrf2	   in	   T-­‐cells	   as	   well	   as	   the	   fundamental	  immunological	   differences	   between	   GVHD	   and	   GVT	   actions,	   but	   also	  potentially	   reveal	   exciting	   therapeutic	   targets	   for	   treating	   patients	   with	  hematologic	  malignancies	  and	  GVHD.	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CHAPTER SIX 
Materials and methods 
 
Mice 
Nrf2-/- mice were a kind gift from Dr. Jefferson Chan (University of California, 
Irvine), and were backcrossed to C57BL/6 background for 7-8 generations.  Wild-
type (Nrf2+/+) C57BL/6 (CD45.2) or B6.SJL-PtprcaPepcb/BoyJ (CD45.1) mice 
were purchased from the Jackson Laboratory (Bar Harbor, ME).  All mice were 
age-matched, female Nrf2+/+ and Nrf2-/- mice (8 to 12 weeks old).  All mice were 
maintained in the MSKCC Animal Facility in Thorensten units with filtered germ-
free air.  Experiments were conducted in compliance with institutional guidelines 
at MSKCC.  
 
Cell Isolation 
BM cells were flushed from intact femurs and tibia, and spleens were mashed with 
glass slides to generate single cell suspension.  Collection of the cells was 
performed in RPMI media with 10% FBS or PBS with 0.5% BSA, and filtered 
through a 70-µm strainer.  Unless otherwise stated, all cell numbers in this study 
were standardized as total counts per leg or per spleen. 
 
Flow Cytometry 
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Monoclonal antibodies (mAbs) recognizing the following markers were used for 
flow cytometric analyses and cell sorting (LSR II or FACSAria III, BD 
Biosciences, NJ): (from BD Pharmingen, NJ) c-kit (2B8), Sca-1 (D7), CD11b 
(M1/70), CD11c (HL3), CD19 (ID3), CD3ε (145-2C11), CD34 (RAM34), CD4 
(RM4-5), CD45 (30-F11), CD45.1 (A20), CD45.2 (104), CD48 (HM48-1), CD8α 
(53-6.7), CD62L (MEL-14), CD135 (A2F10.1), Gr-1 (RB6-8C5), NK1.1 (PK136), 
TER-119 (TER-119), CXCR4 (2B11), VCAM-1 (429), Rat IgG2aκ isotype (B39-
4); (from eBioscience, CA) CD127 (A7R34), CD150 (mShad150), CD16/CD32 
(93); (from Invitrogen, CA) B220 (RA3-6B2), and streptavidin (N/A).  The lineage 
antibody cocktail included anti-CD3, anti-CD4, anti-CD8α, anti-CD19, anti-
CD11b, anti-CD11c, anti-Gr-1, anti-NK1.1, and anti-TER119.  Nuclear staining of 
Ki-67 was done using anti-human Ki-67 antibody (MOPC-21) (BD Pharmingen, 
NJ) and fixation/permeabilisation solutions (eBiosciences, CA).  
 
Colony-Forming Cell Assays 
BM cells (5 × 104) or splenocytes (1 × 105) were plated in triplicate in 35-mm 
tissue culture dishes (Nalge Nunc, NY) containing 1 mL assay medium consisting 
of IMDM, 1.2% methylcellulose (Fisher Scientific, NJ), 30% FBS, 5 × 10–5 M 2-
mercaptoethanol, 2 mM L-glutamine, and 0.5 mM hemin, and supplemented with 
rmSCF (20 ng/mL), rmIL-3 (20 ng/mL), and human erythropoietin (EPO, 6 U/mL) 
(Amgen Inc, CA).  After 10 days of incubation at 37°C in 5% CO2 in air, CFU-
GM, BFU-E, and CFU-Mix were scored under an inverted microscope.  
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Cobblestone Area Forming Cell Assay 
MS-5 cells were seeded in 12.5 cm2 tissue culture flasks in α-MEM with 10% 
FBS.  When the cells reached confluence, medium was replaced with long-term 
culture (LTC) medium: MEM-α, 12.5% FBS, 12.5% horse serum (HyClone Lab. 
Inc., UT), 10–6 M hydrocortisone (Sigma Chemical Co., MO) and 5 × 10-5 M 2-
mercaptoethanol.  BM cells (5 × 105) or Lin- splenocytes (1.5 × 104) were added 
per flask in triplicates.  The cultures were demidepopulated weekly and fed with 
fresh LTC medium.  After 3 weeks of culture, CAFCs were scored as phase-dark 
hematopoietic clones of at least 5 cells beneath the stromal layer using an inverted 
microscope.  After scoring CAFCs at week 3, suspension cells and adherent cells 
that were detached by treatment with 0.05% trypsin/0.53 mM EDTA were assayed 
in methylcellulose for CFU-GM or replated in fresh MS-5 cells for secondary 
CAFC assay.  The co-cultures of secondary CAFC assay were again scored at 
week 3.  
 
Cell Culture 
Co-culture of HSPCs and OP9-DL1 stromal cell lines was previously described 67.  
Briefly, isolated LSK cells were seeded on a 60-80% confluent monolayer of OP9-
DL1 cells into six-well tissue culture plates in α-MEM, supplemented with 20% 
FBS, 100U/mL of penicillin, 100µg/mL of streptomycin, 5ng/mL of rmIL-7 
(Miltenyi Biotec, CA), and rm5ng/mL of Flt3L (Miltenyi Biotec, CA).  Cells were 
maintained at 37oC in a humidified atmosphere containing 5% CO2, and were 
collected at indicated intervals.  
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Bone Marrow Transplant 
In the serial transplantation assay, we purified BM LSK cells from CD45.2+ (WT 
or Nrf2-/-) donors and CD45.1+ (WT) competitors, mixed them at 1:1 ratio, and 
transplanted 2 × 103 cells into lethally irradiated CD45.1+ (WT) mice (1,100 cGy 
total body irradiation, split dose) via tail vein injection.  After 4 months of 
reconstitution, we assessed chimerism of donor-derived LSK cells (CD45.2+) in 
the recipient BM, as well as sort purified these cells, mixed them with new 
CD45.1+ (WT) competitors at 1:1 ratio, and transplanted them into a second set of 
lethally irradiated CD45.1+ (WT) mice.  Chimerism in the BM was again assessed 
4 months after secondary transplant.  In the chimeric repopulation study, we 
isolated LSK cells from donor BM and transplanted 2 × 103 cells into lethally 
irradiated mice, and analysed reconstitution in BM after 8 weeks.  In the in vivo 
homing assays, we isolated Lin- BM cells from CD45.1+ (WT) and CD45.2+ (WT 
or Nrf2-/-) donors using a lineage cell depletion kit (Miltenyi Biotec, CA) per 
manufacturer's instructions.  We labelled the isolated cells with 5µM CellTraceTM 
Violet Cell Proliferation Kit for flow cytometry (Invitrogen, CA) or CFSE 
(Invitrogen, CA) per manufacturer's recommendation, mixed the labelled CD45.1+ 
and CD45.2+ Lin- BM cells at 1:1 ratio, then transplanted 2 × 106 cells into lethally 
irradiated recipients for analysis 18 hours post-transplant.  We also isolated WBM 
cells from CD45.2+ WT and Nrf2-/- donors, labelled them with CellTraceTM Violet 
Cell Proliferation Kit and CFSE respectively, mixed them at 1:1 ratio, then 
transplanted 16 × 106 cells into lethally irradiated recipients for analysis of LT-
HSC engraftment 16 hours following the transplant.   
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Cell Cycle Analysis 
Purified BM cells (LSKs or LT-HSCs) were fixed with ice-cold 4% 
paraformaldehyde at 4oC overnight, washed with PBS twice, then labeled with 
20µg/mL Hoechst 33342 (Invitrogen, CA) and 1µg/mL pyronin Y (Sigma-Aldrich, 
MO) for 20 minutes before flow cytometric analysis.  
 
Immunohistochemistry 
Fresh tibiae were collected and fixed in 10% formalin at room temperature 
overnight, decalcified for 24 hours using Decalcifier I (Surgipath, IL), washed with 
water, and embedded in wax.  5 µm paraffin sections were prepared using a 
microtome (Leica Microsystems, Germany).  The sections were dewaxed in 
xylene, hydrated in graded alcohols, blocked in 1% hydrogen peroxide, and treated 
in pH6.0 10mM citrate buffer.  The sections were then incubated with primary 
antibody Cyclin D1 (Thermo Scientific, MA) overnight, followed by appropriate 
secondary antibodies and avidin-biotin complexes (Vector Laboratories, CA). 
Antibody reaction was visualized with 3-3’ Diaminobenzidine (Sigma-Aldrich, 
MO) and counterstained with haematoxylin.  Tissue sections were dehydrated in 
graded alcohols, cleared in xylene and mounted.  
 
5-FU Treatment 
5-FU (InvivoGen, CA) was administered to mice intraperitoneally at a dose of 
150mg/kg either as a single dose or once every 7 days consecutively for 3 times. 
BM cellularity was examined at day 3.5 in the former experiment, and the survival 
of individual mice was monitored daily in the latter.  
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Transwell Cell Migration Assay 
Purified LSK cells were incubated in IMDM media containing 20% FBS, 20ng/mL 
murine IL-3 (PeproTech Inc., NJ), 20ng/mL SCF (PeproTech Inc., NJ), and 
20ng/mL Flt3L (Amgen Inc., CA) 37oC in a humidified atmosphere containing 5% 
CO2 for 18 hours.  LSK cells were then washed with IMEM media twice, 
resuspended in QBSF media (Quality Biologicals Onc., MD) in 0.1 × 106/mL. 
100µL of cell suspension was loaded to the upper chamber of the transwell, and 
600µL of QBSF media with or without CXCL12 (200ng/mL, R&D systems, MN) 
was added to the lower chamber of the transwell plate (pore size 5µm, Corning, 
NY).  Cells were allowed to migrate across the membrane at 37oC with 5% CO2 
incubator, and their migration efficiency was assessed at 6 hours.  
 
Luciferase Reporter Assay 
CXCR4 promoter regions were identified within 2kb upstream from the 
transcription start site of mouse CXCR4 sequence (Genebank accession number 
NC_000067) as previously described68. Putative Nrf2 binding sites were predicted 
using PROMO (http://www.lsi.upc.es/~alggen).  500bp upstream from 
transcription start site of mouse CXCR4 was amplified by PCR from WT C57BL/6 
mouse genomic DNA and subsequently subcloned into the pGL4.23 luciferase 
reporter vector (Promega, WI), and named pCXCR4.   pCXCR4 construct was co-
transfected into HEK293T cells using lipid-based 293T TransIT Reagent (Mirus 
Bio, WI)  with either pUC19 empty vector or Nrf2- pCMV vector, as well as 
phRL-TK vector as an internal control.  Cells were collected 24 hours after 
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transfection and both luciferase activity was determined using Dual-Luciferase 
Reporter Assay System (Promega, WI) as per manufacturer's instructions.  
 
Chromatin Immunoprecipitation Assay (ChIP) 
ChIP assays were performed using the ChIP Assay Kit (Upstate Biotechnology, 
EMD Millipore, MA) as per manufacturer's instruction.  Mouse WBM cells were 
used to assess the binding of Nrf2 to potential binding sites in Cxcr4 promoter.  
Chromatin was incubated with normal mouse IgG or an anti-Nrf2 antibody (C-20) 
(Santa Cruz, CA).  Input and immunoprecipitated DNA were analyzed by 
quantitative PCR with primer pairs spanning the Nrf2 binding sites identified in 
the Cxcr4 promoter (TBS2: AACCGAAAGCCTTCCTTAGC and 
TGATGATCCCGTTTGTCACC; TBS3: ATCCACGTGGGTAAGGATGG and 
AGAAGTCCAAGAGCCACTGC).  
 
Lentiviral Transduction  
CXCR4 cDNA from pORF-mCXCR4 plasmid (Invivogen, CA) was subcloned 
into a plasmid encoding recombinant lentiviral vector with eGFP reporter (a kind 
gift from Dr. Michel Sadelain).  Viral particles were produced in HEK293T cells 
using lipid-based 293T TransIT Reagent (Mirus Bio, WI) as previously 
described31.  Freshly purified LSK cells were resuspended in 0.2 × 106/mL of 
QBSF media (Quality Biologicals Onc., MD), supplemented with 10ng/mL rmSCF 
(Miltenyi Biotec, CA), 20ng/mL rhIGF-2 (Miltenyi Biotec, CA), 10ng/mL rhFGF 
II (Miltenyi Biotec, CA), 100ng/mL rhTPO (Miltenyi Biotec, CA).  Concentrated 
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viral particles were added to cell suspension with 0.8 µg/mL polybrene and 
spinoculated at 2 × 103RPM for 90min at 22oC.  Cells were collected for 
subsequent assays and eGFP fluorescence determined using flow cytometric 
analysis 48 hours after transduction.  
 
Statistical Analysis 
Data were processed in GraphPad Prism 5.0 software.  Statistical analysis for 
comparisons between two groups was performed with nonparametric unpaired 
Mann-Whitney U test.  Survival data were analyzed with the Mantel-Cox log-rank 
test.  * p < 0.05; ** p < 0.01; and *** p < 0.005 were considered as statistically 
significant.  
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